Anticancer candidate inhibits drug-induced hyperglycaemia


Monday, 26 October, 2020


Anticancer candidate inhibits drug-induced hyperglycaemia

A new anticancer drug candidate, developed by clinical-stage oncology company SynDevRx, offers a way to inhibit both tumour growth and drug-induced hyperglycaemia in multiple models of HR+ breast cancer, as demonstrated in a recent series of preclinical studies.

Many types of cancer are commonly treated with PI3K/Akt therapies, but these drugs often induce hyperglycaemia (high blood glucose) — especially in patients who already have metabolic complications such as obesity, pre-diabetes or type 2 diabetes. Hyperglycaemia can lead to drug holidays and, in serious cases, can cause treatment-induced resistance in tumours.

Aiming to address the interplay between metabolic dysfunction and cancer, SynDevRx developed SDX-7320, which works by inhibiting MetAP2 — a clinically validated target that plays a key role in tumour growth, metastasis, angiogenesis and metabolic hormone dysfunction.

In a series of efficacy and safety studies in a variety of syngeneic cancer models (breast, melanoma), SDX-7320 displayed single agent anti-tumour activity while improving metabolic dysfunction (in particular, hyperglycaemia, insulin resistance and leptin resistance). SDX-7320 prevented the hyperglycaemia and hyperinsulinemia associated with Piqray (Novartis’s PI3Kα inhibitor) administration in normal mice — serious side effects of drugs from these classes that have been reported to lead to treatment resistance. Furthermore, in a xenograft model of ER+/Her2- breast cancer, SDX-7320 and Piqray (alpelisib), administered together at low doses, showed synergy at inhibiting tumour growth.

“Piqray is an important new therapy for patients with HR+/Her2-, metastatic breast cancer whose tumours have a mutation in the PIK3CA gene,” said Jim Shanahan, co-founder and Chief Business Officer of SynDevRx. “However, drugs that target the PI3K/Akt pathway frequently cause hyperglycaemia in patients, especially those with high baseline fasting glucose, HbA1c, insulin resistance, pre-diabetes, type 2 diabetes or obesity.

“Treatment-induced hyperglycaemia has been reported as a safety concern that can lead to dose interruptions and/or drug holidays. In addition, the treatment-induced hyperglycaemia leads to hyperinsulinemia, which in preclinical studies has been shown to cause resistance to these drug classes. Baseline systemic metabolic complications, such as obesity, pre-diabetes or type 2 diabetes, were reported to correlate with and predict worse outcomes for many breast cancer patients taking Piqray.”

Preclinical studies of SDX-7320 with another drug from the PI3k/Akt class, the Akt/mTOR inhibitor known as capivasertib (AstraZeneca), showed that SDX-7320 also attenuated treatment-induced hyperglycaemia (in normal mice) and inhibited tumour growth in a xenograft model of HR+/Her2+ breast cancer. According to Shanahan, “Our preclinical data with alpelisib (Piqray) and capivasertib suggests that SDX-7320 may make drugs targeting the PI3k/Akt/mTOR pathway safer and more effective by controlling blood glucose and insulin levels in combination with tumour growth inhibition.”

SynDevRx will soon commence Phase 2 studies in late-stage ER+/Her2- breast cancer patients.

Image credit: ©stock.adobe.com/au/Voyagerix

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Related News

'Egg-cess' consumption linked to diabetes

The health benefits of the humble egg might not be all they're cracked up to be, as a...

Gut microbiome linked to deadly lung disease

Australian researchers have shown for the first time a link between chronic obstructive pulmonary...

Alzheimer's drug could help fight antibiotic resistance

An experimental Alzheimer's disease treatment is proving effective at treating some of the...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd